Status:
COMPLETED
Role of Pseudogene in Incontinentia Pigmenti, and Its Potential Treatment
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
National Science and Technology Council, Taiwan
Conditions:
Incontinentia Pigmenti
Eligibility:
All Genders
Brief Summary
Incontinentia Pigmenti (IP) is an X-linked dominant ectodermal dysplastic disorder. It is due to loss of function of NF-Kappa B Essential Modulator (NEMO, inhibitor of Kappa light polypeptide gene enh...
Eligibility Criteria
Inclusion
- Patients diagnosed to have Incontinentia Pigmenti
Exclusion
- None
Key Trial Info
Start Date :
August 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00976586
Start Date
August 1 2009
End Date
June 1 2012
Last Update
December 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100